|
Carfilzomib-lenalidomide-dexamethasone (KRd) vs carfilzomib-cyclophosphamide-dexamethasone (KCd) induction: Planned interim analysis of the randomized FORTE trial in newly diagnosed multiple myeloma (NDMM). |
|
|
Honoraria - Amgen; Bristol-Myers Squibb; Celgene; Janssen; Takeda |
Consulting or Advisory Role - Roche; Seagen; Takeda |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Amgen; Celgene; Janssen; Mundipharma; Sanofi |
|
|
Honoraria - Amgen; Bristol-Myers Squibb; Celgene; Janssen; Takeda |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Amgen; Celgene |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Bristol-Myers Squibb; Celgene; Janssen; Sigma-Tau |
|
|
No Relationships to Disclose |
|
|
|
Honoraria - Genmab; Janssen-Cilag; Takeda |
Consulting or Advisory Role - Genmab; Janssen-Cilag; Takeda |
Research Funding - Genmab (Inst); Janssen-Cilag (Inst); Takeda (Inst) |
|
|
No Relationships to Disclose |
|
|
Honoraria - Abbvie; Amgen; Bristol-Myers Squibb; Celgene; Janssen; Novartis; Sanofi |
Research Funding - Amgen; Bristol-Myers Squibb; Celgene; Janssen; Mundipharma; Novartis; Sanofi |